ACE-083 ( DrugBank: - )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
10	シャルコー・マリー・トゥース病	2
113	筋ジストロフィー	4

10. シャルコー・マリー・トゥース病

臨床試験数 : 39 / 薬物数 : 44 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03943290 (ClinicalTrials.gov)	May 10, 2019	17/4/2019	Extension Study to Evaluate the Long-Term Effects of ACE-083in Patients With Facioscapulohumeral Mus ...	An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083in Patients With Facioscap ...	Facioscapulohumeral Muscular Dystrophy;Charcot-Marie-Tooth Disease	Drug: ACE-083	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	62	Phase 2	United States;Canada;Spain
2	NCT03124459 (ClinicalTrials.gov)	July 31, 2017	12/4/2017	Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083in Patients With Charcot-Mari ...	Charcot-Marie-Tooth Disease	Drug: ACE-083;Drug: Placebo	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	62	Phase 2	United States

First Previous1Next Last

113. 筋ジストロフィー

臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-000305-79-ES (EUCTR)	14/05/2019	12/04/2019	An extension study to the A083-02 and A083-03 studies that evaluate the long-term effect of the ACE- ...	An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083in Patients with Facioscap ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: ACE-083 Product Code: ACE-083 INN or Proposed INN: pending Other descriptive name: ACE-08 ...	Acceleron Pharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	150	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Canada;Spain
2	NCT03943290 (ClinicalTrials.gov)	May 10, 2019	17/4/2019	Extension Study to Evaluate the Long-Term Effects of ACE-083in Patients With Facioscapulohumeral Mus ...	An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083in Patients With Facioscap ...	Facioscapulohumeral Muscular Dystrophy;Charcot-Marie-Tooth Disease	Drug: ACE-083	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	62	Phase 2	United States;Canada;Spain
3	EUCTR2016-003257-15-ES (EUCTR)	12/04/2018	04/01/2018	A Phase 2 clinical trial that is randomized and controlled by a placebo (similar to the product unde ...	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083in Patients with Facioscapulo ...	Facioscapulohumeral Muscular Dystrophy MedDRA version: 20.0;Level: PT;Classification code 10064087;T ...	Product Name: ACE-083 Product Code: ACE-083 INN or Proposed INN: pending Other descriptive name: ACE-08 ...	Acceleron Pharma Inc.	NULL	Not Recruiting			Female: yes Male: yes	92	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Canada;Spain
4	NCT02927080 (ClinicalTrials.gov)	November 2016	5/10/2016	Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083in Patients With Facioscapulo ...	Facioscapulohumeral Muscular Dystrophy	Drug: ACE-083;Drug: ACE-083 or placebo	Acceleron Pharma, Inc.	NULL	Terminated	18 Years	N/A	All	95	Phase 2	United States;Canada;Spain

First Previous1Next Last

先頭へ